Use of preoperative serum CA‐125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer

Acta Obstetricia et Gynecologica Scandinavica - Tập 85 Số 12 - Trang 1501-1505 - 2006
Hyun Hoon Chung1, Jae‐Weon Kim1, N.H. Park1, Yong Sang Song1, Soon‐Beom Kang1, HYO‐PYO LEE1
1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea

Tóm tắt

AbstractBackground. The purpose of this study was to evaluate the predictive value of preoperative serum CA‐125 levels in the assessment of disease extent and clinical outcome of endometrial cancer. Method. This retrospective study evaluated 92 women with pathologically proven endometrial carcinoma scheduled for treatment that had preoperative serum CA‐125 levels between January 1999 and February 2006. The association of preoperative serum CA‐125 with a variety of histopathologic factors was evaluated. Statistical analysis was performed using φ2/Fisher's exact test and a logistic regression. Survival was studied with the Kaplan–Meier method and Cox regression models. Results. Elevated serum CA‐125 levels were significantly correlated with advanced‐stage disease (p<0.001), lymph node metastases (p<0.001), increased depth of myometrial invasion (p = 0.001), and positive peritoneal cytology (p = 0.026). Multivariate analyses using logistic regression showed that lymph node metastases had the most significant effect on the elevation of preoperative serum CA‐125 levels (p = 0.004). Patients with a serum CA‐125 ≤28.5 U/ml had a significantly better five‐year disease‐free survival than those with an elevated level in this study: 85.6% versus 60.0% (p = 0.004). Conclusions. The preoperative serum CA‐125 level appears to be a significant independent predictor of lymph node metastasis and prognosis after surgical intervention. Therefore, preoperative serum CA‐125 may be a useful tool, in the clinical setting, for optimal individualized patient management.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.54.1.8

10.1002/1097-0142(19901015)60:8 <2035::AID-CNCR2820601515>3.0.CO;2-8

Boronow RC, 1984, Surgical staging in endometrial cancer: clinical‐pathologic findings of a prospective study, Obstet Gynecol, 63, 825

10.1046/j.1525-1438.1994.04050306.x

10.1097/00006250-199102000-00024

10.1016/S0002-9378(84)90444-7

10.1016/0002-9378(86)90358-3

Rose PG, 1994, Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma, Obstet Gynecol, 84, 12

10.1016/0002-9378(88)90163-9

10.1006/gyno.1994.1213

Powell JL, 2005, Preoperative serum CA12‐5 levels in treating endometrial cancer, J Reprod Med, 50, 585

10.1093/jnci/dji102

10.1016/0002-9378(85)90371-0

10.1016/0002-9378(90)90692-Z

10.1006/gyno.1994.1217

10.1016/S0029-7844(97)00286-X

10.1097/01.pgp.0000161883.06519.94

National Statistical Office RoK.The Causes of Death Statistics (Death and Death rates).2004.

Peters‐Engl C, 1998, TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early‐stage endometrial cancer, Anticancer Res, 18, 4635

Koper NP, 1998, Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy, Anticancer Res, 18, 1897

10.1016/j.ygyno.2004.07.016

Santala M, 2003, Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer, Anticancer Res, 23, 3097

10.1006/gyno.1994.1093

Thông tin
Thông tin xuất bản

Acta Obstetricia et Gynecologica Scandinavica

Tập 85 Số 12

1501-1505

Thông tin tác giả